Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. 2000

T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
Department of Internal Medicine, Division of Hematology/Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, USA.

Sequential administration of LPS to SCID mice results in the generalized Shwartzman reaction, manifesting as rapid mortality via cytokine-induced shock. Here we demonstrate that in vivo neutralization of IL-15 before LPS priming significantly reduced lethality in this reaction (p = 0.0172). We hypothesize that LPS priming induces IL-12 and IL-15 that costimulate NK cell-derived IFN-gamma. Such IFN-gamma may then in turn sensitize macrophages to elicit the Shwartzman reaction following a subsequent LPS challenge. Supporting this, IL-12 and IL-15 synergized to induce murine NK cell IFN-gamma production in vitro. LPS stimulation of SCID mouse splenocytes resulted in measurable IFN-gamma production, which was reduced when IL-15 was neutralized or IL-2/15Rbeta was blocked. Pretreatment with either anti-IL-2/15Rbeta or anti-IL-15 Abs reduced serum IFN-gamma protein following LPS administration to SCID mice. Collectively, these data provide the first in vivo evidence that IL-15 participates in LPS-induced innate immune IFN-gamma production and significantly contributes to the lethal Shwartzman reaction.

UI MeSH Term Description Entries
D007106 Immune Sera Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. Antisera,Immune Serums,Sera, Immune,Serums, Immune
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012790 Shwartzman Phenomenon Hemorrhagic necrosis that was first demonstrated in rabbits with a two-step reaction, an initial local (intradermal) or general (intravenous) injection of a priming endotoxin (ENDOTOXINS) followed by a second intravenous endotoxin injection (provoking agent) 24 h later. The acute inflammation damages the small blood vessels. The following intravascular coagulation leads to capillary and venous THROMBOSIS and NECROSIS. Shwartzman phenomenon can also occur in other species with a single injection of a provoking agent, and during infections or pregnancy. Its susceptibility depends on the status of IMMUNE SYSTEM, coagulation, FIBRINOLYSIS, and blood flow. Schwartzman Phenomenon,Shwartzman Reaction,Schwartzman Reaction,Phenomenon, Schwartzman,Phenomenon, Shwartzman,Schwartzman Reactions
D013154 Spleen An encapsulated lymphatic organ through which venous blood filters.

Related Publications

T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
April 1998, Journal of immunology (Baltimore, Md. : 1950),
T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
August 2004, Journal of immunology (Baltimore, Md. : 1950),
T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
February 2009, Journal of immunology (Baltimore, Md. : 1950),
T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
January 2008, Journal of immunology (Baltimore, Md. : 1950),
T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
March 2012, Journal of immunology (Baltimore, Md. : 1950),
T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
January 2010, Journal of immunology (Baltimore, Md. : 1950),
T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
June 2007, Journal of immunology (Baltimore, Md. : 1950),
T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
December 2005, Journal of immunology (Baltimore, Md. : 1950),
T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
April 2010, Journal of immunology (Baltimore, Md. : 1950),
T A Fehniger, and H Yu, and M A Cooper, and K Suzuki, and M H Shah, and M A Caligiuri
July 2002, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!